Clinical trials: Stem Cell Mobilization
Immunosuppression, Leukemia
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor s T cells (a type of lymphocyte, or white blood cell) have been removed and then added back.
- Trial name
- NCT00353860
- Testing
- SOLEX 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to…
- Trial name
- NCT00002674
- Testing
- filgrastim, cytarabine, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Adenosine Deaminase Severe Combined Immune Deficiency
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human…
- Trial name
- NCT05432310
- Testing
- A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Los Angeles
Lymphoma
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Primary Objectives: 1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups. 2. To determine the number of apheresis procedures, total stem cell yield/kg patient body weight and the toxicity…
- Trial name
- NCT00499343
- Testing
- Etoposide, G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer).
- Trial name
- NCT01010880
- Testing
- BKT140
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- Biokine Therapeutics Ltd
Graft vs Host Disease, Hematologic Neoplasm
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
Bone marrow transplants (BMT) are one of the accepted therapies used to treat leukemia. However, BMT have risks of complications. One potentially life-threatening complication is known as graft-versus-host disease (GVHD).
- Conditions
- Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma
- Trial name
- NCT00001623
- Testing
- Allogeneic Bone Marrow Transplant
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Coronary Artery Disease
Age and Endothelial Progenitor Cell Mobilization
It is hypothesized that aging is associated with reduced vascular injury-induced endothelial progenitor cell activity, resulting in impaired vascular repair and increased vascular disease.
- Trial name
- AGE-PCI (NCT00585949)
- Testing
- Percutaneous Coronary Angioplasty, Angiography
- Where
- 2 sites in United States
- Volunteers
- 123 people
- Sponsor
- Emory University
Coronary Artery Disease
Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease
This two-part study will determine whether stem cells (primitive cells produced by the bone marrow that can develop into blood cells or other types of cells) can be pushed out into the bloodstream, relocate in the heart, and grow…
- Trial name
- NCT00043628
- Testing
- Stem Cell Mobilization
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Mastocytosis
Stem Cell Transplantation to Treat Systemic Mastocytosis
This study will investigate the safety and effectiveness of an experimental stem cell transplant procedure for treating mastocytosis-a disease of abnormal mast cell growth.
- Trial name
- NCT00006413
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Leukemia
Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia
Allogeneic stem cell transplantation (Allo-HSCT) is the effective and even the only treatment for hematological malignancies. The "GIAC" protocol established by our center has successfully crossed the HLA barrier in…
- Trial name
- NCT03756675
- Testing
- haplotype PBSCT
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Congenital Hemolytic Anemia, Sickle Cell Disease
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
People with severe congenital anemias, such as sickle cell anemia and beta-thalassemia, have been cured with bone marrow transplantation (BMT).
- Trial name
- NCT00061568
- Testing
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Myeloproliferative Disorders
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
The study is designed as a Phase III, randomized, open label, multicenter, prospective, comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) versus marrow from unrelated…
- Conditions
- Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00075816
- Testing
- Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation
- Where
- 45 sites in United States, Canada
- Volunteers
- 551 people
- Sponsor
- Medical College of Wisconsin
Graft vs Host Disease, Hematologic Neoplasms
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies
Many patients with hematological malignancies potentially curable by bone marrow transplantation are not considered for transplantation because an HLA identical family or unrelated donor is unavailable.
- Conditions
- Graft vs Host Disease, Hematologic Neoplasms, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00001748
- Testing
- Peripheral blood progenitor cell transplant
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00027937
- Testing
- aldesleukin, filgrastim, sargramostim
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Stem Cell Transplantation, Hematopoietic, Poor Graft Function
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Poor Graft Function, Delayed Platelet Engraftment, Hematological Diseases
- Trial name
- NCT02240992
- Testing
- PBSC, MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Leukemia
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell or bone marrow transplantation may be able to replace immune cells that were destroyed…
- Trial name
- NCT00002789
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Poor Graft Function, Stem Cell Transplantation
G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation
Poor graft function (PGF) is a common complication after allogeneic stem cell transplantation, which was associated with high mortality. The pathogenesis fo PGF was poorly understood.
- Conditions
- Poor Graft Function, Stem Cell Transplantation, Graft Versus Host Disease
- Trial name
- NCT01857336
- Testing
- infusion of G-CSF mobilized peripheral harvest
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Stem Cell Transplantation, Hematopoietic, Poor Graft Function
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with Granulocyte Colony-Stimulating Factor (G-CSF) mobilized…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Poor Graft Function, Hematological Diseases
- Trial name
- NCT02083718
- Testing
- PBSC, MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
RATIONALE: Giving chemotherapy before a donor peripheral stem cell transplant or bone marrow transplant using stem cells from a brother or sister that closely match the patient's stem cells, helps stop the growth of cancer or…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00438958
- Testing
- filgrastim, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 230 people
- Sponsor
- The Canadian Blood and Marrow Transplant Group
Solid Malignancies
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study.
- Trial name
- NCT00695370
- Testing
- Pegfilgrastim (drug)
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand